Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of the National Cancer Institute|May 28, 2010
Effect of noncompetitive proteasome inhibition on bortezomib resistanceXiaoming Li, Tabitha E Wood, Remco Sprangers, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
JCI Insight|May 7, 2016
Identification of human plasma cells with a lamprey monoclonal antibodyCuiling Yu, Yanling Liu, Justin Tze Ho Chan, et al.
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
American Journal of Hematology|November 26, 2013
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignanciesMark D Minden, Donna E Hogge, Scott J Weir, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2016
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte BindingPenka S Petrova, Natasja Nielsen Viller, Mark Wong, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
The New England Journal of Medicine|December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and TeclistamabShaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
Pageof 11